Literature DB >> 16769090

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Judith A Siuciak1, Sheryl A McCarthy, Douglas S Chapin, Remie A Fujiwara, Larry C James, Robert D Williams, Jeffrey L Stock, John D McNeish, Christine A Strick, Frank S Menniti, Christopher J Schmidt.   

Abstract

PDE10A is a newly identified phosphodiesterase that is highly expressed by the medium spiny projection neurons of the striatum. In order to investigate the physiological role of PDE10A in the central nervous system, PDE10A knockout mice (PDE10A(-/-)) were characterized both behaviorally and neurochemically. PDE10A(-/-) mice showed decreased exploratory activity and a significant delay in the acquisition of conditioned avoidance behavior when compared to wild-type (PDE10A(+/+)) mice. However, in a variety of other well-characterized behavioral tasks, including the elevated plus maze (anxiety), forced swim test (depression), hot plate (nociception) and two memory models (passive avoidance and Morris water maze), PDE10A(-/-) mice performed similarly to wild-type mice. When challenged with PCP or MK-801, PDE10A(-/-) mice showed a blunted locomotor response in comparison to PDE10A(+/+) mice. In contrast, PDE10A(-/-) and PDE10A(+/+) mice responded similarly to the locomotor stimulating effects of amphetamine and methamphetamine. Our findings suggest that PDE10A is involved in regulating striatal output, possibly by reducing the sensitivity of medium spiny neurons to glutamatergic excitation. These results are discussed in relationship to the hypothesis that PDE10A inhibition presents a novel treatment for psychosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769090     DOI: 10.1016/j.neuropharm.2006.01.012

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  66 in total

1.  Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test.

Authors:  Barbara Langen; Rita Dost; Ute Egerland; Hans Stange; Norbert Hoefgen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-16       Impact factor: 4.530

Review 2.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

3.  Dopamine D2 receptor-dependent modulation of striatal NO synthase activity.

Authors:  Stephen Sammut; Kristina E Bray; Anthony R West
Journal:  Psychopharmacology (Berl)       Date:  2007-01-06       Impact factor: 4.530

4.  Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.

Authors:  Z Xie; W O Adamowicz; W D Eldred; A B Jakowski; R J Kleiman; D G Morton; D T Stephenson; C A Strick; R D Williams; F S Menniti
Journal:  Neuroscience       Date:  2006-02-17       Impact factor: 3.590

5.  Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation.

Authors:  Sarah Threlfell; Stephen Sammut; Frank S Menniti; Christopher J Schmidt; Anthony R West
Journal:  J Pharmacol Exp Ther       Date:  2008-12-04       Impact factor: 4.030

6.  Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum.

Authors:  Corina Russwurm; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

Review 7.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo.

Authors:  Stephen Sammut; Sarah Threlfell; Anthony R West
Journal:  Neuropharmacology       Date:  2009-12-05       Impact factor: 5.250

Review 9.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.